STOCK TITAN

Calliditas Therapeutics AB - CALT STOCK NEWS

Welcome to our dedicated news page for Calliditas Therapeutics AB (Ticker: CALT), a resource for investors and traders seeking the latest updates and insights on Calliditas Therapeutics AB.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Calliditas Therapeutics AB's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Calliditas Therapeutics AB's position in the market.

Rhea-AI Summary
Calliditas reports net sales of SEK 294.6 million for Q3 2023, with TARPEYO® net sales amounting to SEK 283.6 million. Operating loss for the quarter was SEK 159.6 million. The company reconfirms its guidance for 2023 with a projected net sales of USD 100 – 120 million from TARPEYO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
none
-
Rhea-AI Summary
Calliditas Therapeutics presented additional data analyses from the Phase 3 NefIgArd study at the American Society of Nephrology Kidney Week 2023. The study evaluated Nefecon in adults with primary IgA nephropathy and showed a delayed progression to a 30% eGFR reduction compared to placebo. Nefecon also resulted in lower deterioration in renal function, reduced urine protein creatinine ratio, and decreased microhematuria. Serum biomarker analysis demonstrated a disease-modifying effect of Nefecon. Modeling analysis predicted a substantial delay in renal failure progression. Setanaxib, a dual NOX inhibitor, showed promising results in reducing fibrosis and glomerular sclerosis in a mouse model of Alport syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
-
Rhea-AI Summary
Calliditas Therapeutics announces approval of Nefecon in Macau for the treatment of IgA nephropathy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
none
Rhea-AI Summary
Calliditas Therapeutics' major owners appoint nomination committee for AGM 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
none
-
Rhea-AI Summary
Calliditas Therapeutics announces abstract presentations at upcoming American Society of Nephrology Kidney Week 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
conferences
-
Rhea-AI Summary
Calliditas receives positive opinion for orphan drug designation for setanaxib in Alport syndrome from European Medicines Agency
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
none
Rhea-AI Summary
Everest Medicines' partner, Calliditas Therapeutics, presented positive findings from biomarker and patient subgroup analyses of Nefecon®'s Phase 3 NefIgArd study. The treatment showed a decrease in IgA-IC levels and modulation of the intestinal immune network. It also demonstrated preservation of kidney function in Asian and White patients with IgAN.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
-
Rhea-AI Summary
Calliditas partner STADA submits request for full marketing authorization for Kinpeygo in the UK for IgA nephropathy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
none
-
Rhea-AI Summary
Calliditas Therapeutics announced positive findings from biomarker and subgroup analyses of Phase 3 NefIgArd study with Nefecon in adults with IgA nephropathy. Nefecon treatment resulted in a decrease in IgA-containing immune complexes levels and modulation of immune abnormalities. Levels of BAFF, APRIL, and sBCMA were decreased, indicating a disease-modifying effect. Treatment with Nefecon preserved kidney function in both Asian and White patients. Nefecon showed significant benefits in eGFR, proteinuria reduction, and decrease in microhematuria. TARPEYO is indicated to reduce proteinuria in adults with IgAN. Important safety information provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
Rhea-AI Summary
STADA and Calliditas submit request to EMA to convert conditional marketing authorization for Kinpeygo treatment for primary IgA nephropathy to standard marketing authorization. Kinpeygo is the first approved treatment in Europe for IgAN. Submission based on full two-year data set from Phase 3 NefIgArd trial. Positive results showed significant benefit in estimated glomerular filtration rate. Companies optimistic about bringing therapy to more patients in Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.19%
Tags
none
Calliditas Therapeutics AB

Nasdaq:CALT

CALT Rankings

CALT Stock Data

545.72M
37.48M
3.18%
0.01%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Sweden
Stockholm

About CALT

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.